Quell Therapeutics

Quell Therapeutics is advancing engineered regulatory T-cell therapies designed to restore immune balance in autoimmune and inflammatory diseases. On the latest episode of the #MovingMedicineForward podcast, Luke Devey, Chief Medical Officer at Quell Therapeutics, and Savannah Doliboa, Chief Commercial Officer at CTI, explore the development of Treg cell therapies, the complexities of launching cell therapy trials across Europe, and the collaboration helping accelerate innovation for patients in need of new treatment options. Listen now: https://lnkd.in/gp5EjMFe

Another very exciting day at Quell today as we initiate another clinical site for the CHILL study at Hospital Universitario Fundación Jiménez Díaz alongside Esperanza Naredo, Otto Martin Olivas Vergara, Paula Sánchez, Raquel Largo, Lucía Llanos, Rocío Cortés, Sara Salamanca Postigo JESÚS FUEYO and our Quell team Luke Devey Sarah-Jayne Reilly Keira Morgan! It was a pleasure to meet with the team in Madrid who gave us a warm welcome with lots of energy and several potential patients already identified for the CHILL study. Today’s initiation brings us to nine initiated sites across the UK, Germany and Spain: Oxford, Leeds, Newcastle, Birmingham, Royal Free London, Reading (referral site for Oxford), Düsseldorf, Erlangen and Madrid reflecting strong momentum behind the CHILL program. CHILL is a Phase 1/2 multinational basket study evaluating QEL-005, our Treg cell therapy, in patients with Refractory Rheumatoid Arthritis and Systemic Sclerosis. With active recruitment now underway, we are advancing a differentiated approach with QEL-005: aiming to restore immune balance rather than relying solely on B cell depletion - “CHILL, not KILL.” https://lnkd.in/efuPGgS6 #SSc #RA #Tregs #Autoimmunity

An exciting day at Quell today as we initiate another clinical site for the CHILL study at FAU Erlangen-Nürnberg alongside Georg Schett, Melanie Hagen, Andreas Mackensen Ricardo Grieshaber-Bouyer, Christian Schmidt and our Quell team Luke Devey and Gareth Wright! Today’s initiation brings us to eight initiated sites across the UK and Germany: Oxford, Leeds, Newcastle, Birmingham, Royal Free London, Reading (referral site for Oxford), Düsseldorf and Erlangen reflecting strong momentum behind the CHILL program. Additional sites across Germany, Spain, and the UK are progressing toward initiation in the coming weeks. CHILL is a Phase 1/2 multinational basket study evaluating QEL-005, our Treg cell therapy, in patients with Refractory Rheumatoid Arthritis and Systemic Sclerosis. With active recruitment now underway, we are advancing a differentiated approach with QEL-005: aiming to restore immune balance rather than relying solely on B cell depletion - “CHILL, not KILL.” https://lnkd.in/efuPGgS6 #SSc #RA #Tregs #Autoimmunity

It was a pleasure to share the Quell Therapeutics story at the 10th Annual Venrock European Investor Tour in London this week. Many thanks to the co-hosts Meru Advisors and Bain Capital and to the sponsors Cowen Inc., Stout and Davis Polk & Wardwell LLP. We were grateful for the opportunity to share our story with a room full of the top US and European investors and to be part of such a thoughtful program.

🎙️ New Episode of The BioHub - by Avetix Luke Henry - CBO/COO of Quell Therapeutics Quell Therapeutics are an exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions. In this we discuss: - How Quell has evolved scientifically, operationally, and strategically in the 7 years Luke has been with the company. - Quell Therapeutics pipeline and what differentiates Quell’s approach from other cell therapy or Treg-focused companies in the space. - The importance of Business Development in market downturns. - The next major value inflection points for the company. ⬇️ Link in the comments

On World Scleroderma Day, we recognise the ongoing challenges faced by people living with systemic sclerosis. Despite advances in immunology, there remains limited treatment options for systemic sclerosis and a substantial unmet need. At Quell Therapeutics, we are working to address this gap through our CHILL Phase 1/2 study, which is evaluating QEL-005, our targeted regulatory T cell (Treg) therapy, in patients with systemic sclerosis and refractory rheumatoid arthritis. Our approach is grounded in restoring immune balance, with the aim of delivering durable, targeted control of complex autoimmune disease. With clinical sites now initiated across the UK and Europe and recruitment underway, we are encouraged by the progress of the CHILL program and remain committed to advancing novel therapies for patients who urgently need new options. Click here to learn more about the CHILL study: https://lnkd.in/efuPGgS6 #WorldSclerodermaDay #SystemicSclerosis #AutoimmuneDisease #CellTherapy #ClinicalTrials #BiotechInnovation #Tregs

An exciting milestone for Quell today as we initiate our first clinical site in Germany at University of Düsseldorf for the CHILL study, alongside Jörg Distler Dr. med. Christina Düsing, Ben-Niklas Bärmann, Alexander Hölscher, Christina Hoffmann Christian Schmidt and our Quell team: Luke Devey Gareth Wright and Sarah-Jayne Reilly! Today’s initiation brings us to seven active sites across the UK and Germany: Birmingham, Royal Free London, Leeds, Newcastle, Oxford, Reading (referral site for Oxford), and Düsseldorf, reflecting strong momentum behind the CHILL program. Additional sites across Germany, Spain, and the UK are progressing toward initiation in the coming weeks. CHILL is a Phase 1/2 multinational basket study evaluating QEL-005, our Treg cell therapy, in patients with Refractory Rheumatoid Arthritis and Systemic Sclerosis. With active recruitment now underway, we are advancing a differentiated approach with QEL-005: aiming to restore immune balance rather than relying solely on B cell depletion - “CHILL, not KILL.” https://lnkd.in/efuPGgS6 #SSc #RA #Tregs #Autoimmunity

We’re delighted to be at the Federation of Clinical Immunology Societies (FOCIS) 2026 Annual Meeting in San Francisco this week! Marc Martinez-Llordella, VP Biology and Co-founder of Quell, will share additional pre-clinical data on QEL-005, our novel CD19 targeted regulatory T cell (Treg) therapy candidate, together with an update on our CHILL clinical study in refractory Rheumatoid Arthritis and Systemic Sclerosis. CHILL is a multinational clinical study that will recruit participants in the UK, Germany and Spain, with patient enrolment underway at leading clinical centres across the UK. Early clinical findings are expected during Q1 2027. Click here to learn more about the CHILL study: https://lnkd.in/efuPGgS6